Ventyx Biosciences Inc. (VTYX)
1.04
-0.02 (-1.89%)
Apr 03, 2025, 12:36 PM - Market open
-1.89% (1D)
| Bid | 0.96 |
| Market Cap | 74.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.97 |
| PE Ratio (ttm) | -0.53 |
| Forward PE | -0.91 |
| Analyst | Buy |
| Ask | 1.12 |
| Volume | 598,074 |
| Avg. Volume (20D) | 1,225,350 |
| Open | 1.02 |
| Previous Close | 1.06 |
| Day's Range | 0.99 - 1.06 |
| 52-Week Range | 0.99 - 5.66 |
| Beta | 0.58 |
About VTYX
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002,...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 21, 2021
Employees 79
Stock Exchange NASDAQ
Ticker Symbol VTYX
Website https://www.ventyxbio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for VTYX stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 952.63% from the latest price.
Stock Forecasts6 months ago
+6.96%
Ventyx Biosciences shares are trading higher after...
Unlock content with
Pro Subscription
8 months ago
-22.71%
Ventyx Biosciences shares are trading lower after the company announced its Phase 2 trial of VTX958 for Crohn's disease did not meet its primary endpoint.
